Company Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, Bronchiectasis & COPD Innovation - MANNKIND CORP

Financial Performance:

• Mankind derived approximately 60% of Q2 revenue from United Therapeutics royalties and manufacturing agreements.
• Mankind's AFRISA sales declined 7% year-over-year; however, new pediatric sales have already surpassed adult market share within 90 days.
• Mankind reported sufficient cash to fund current investments, including two product launches and a Phase 2 trial, with a path to profitability next year without requiring additional capital raises.
• Vicor Pharma disclosed sufficient capital to complete its Phase 2b ASPIRE trial and maintain a cash runway for one year post-completion.
• Mankind acquired SC Pharma in the previous year to diversify into heart failure, a deal reported to have met all expectations regarding cost savings and delivery.

Guidance and Future Outlook:

• Vicor expects top-line results from its Phase 2b ASPIRE trial (Biloxibutide) in mid-2027, following enrollment completion in April 2024.
• Mankind anticipates an acceleration in FY25 growth driven by the return of Tyvaso DPI sales following a recent settlement with United Therapeutics and the launch of Fero6 in Q4.
• Mankind projects the new Fero6 auto-injector to capture the majority of new prescriptions quickly, with Q4 expected to show a strong growth inflection.
• Mankind plans to initiate human trials for its new inhaled program "General D" (RAL DPI) by end-of-year 2024, with Phase 2 data for IPF expected in late 2025.
• Vicor indicates that while a Phase 3 trial will likely be required for regulatory filing, the Phase 2b dataset is considered registrational quality.

Business Segments and Product Lines:

• Vicor Pharma: Developing Biloxibutide (AT2 receptor agonist) for IPF; mechanism focuses on epithelial repair and fibrosis resolution via MMP13 upregulation. The Phase 2b trial enrolls ~400 patients testing 50mg and 100mg doses over 52 weeks.
• Mankind: Launching Nantetinib (inhalation) into Phase 2b (Inflow 2) with ~140 patients across 12-13 countries to address oral GI side effects. Previously reported safety in Phase 1b.
• Mankind (Heart Failure): Launched Fero6 (Bumetanide auto-injector) in late September following SC Pharma acquisition; converting patients from on-body infusioners to the 10-second auto-injector.
• Mankind (Pipeline): Exploring potential inhaled versions of Nintedanib and other combination therapies; "General D" program targeting IPF via AI-predicted efficacy improvements (potentially 150ml FVC delta).
• Mankind (Revenue Mix): Shifting salesforce focus to nephrology and pediatrics to reduce dependence on adult respiratory markets and United Therapeutics royalties.

Market and Competitive Landscape:

• The IPF therapeutic landscape is shifting toward combination therapies and improved tolerability, as existing standard of care (nintedanib, pirfenidone, nardamilast) face limits due to GI side effects.
• Vicor positions Biloxibutide as a unique mechanism targeting epithelial regeneration, potentially offering regenerative rather than just disease-slowing benefits.
• Mankind views the inhalation route as a critical differentiator for IPF to avoid oral GI toxicity and aims to become a "trifecta" alongside Tyvaso and Nintedanib for lung-targeted delivery.
• In heart failure, Mankind sees a continued unmet need for home-based IV-equivalent therapies (Bumetanide) as nasal formulations have shown inferior efficacy compared to IV furosemide.
• The FDA remains conservative on IPF indications for inhaled therapies, likely requiring Phase 3 efficacy trials rather than relying solely on PK/PD data for label expansion to IPF.

Risks and Challenges:

• Vicor faces the risk that its Phase 2a open-label signal (lung function improvement) may not translate to efficacy in the larger, controlled Phase 2b trial.
• Mankind faces a continued revenue concentration risk (60% from United Therapeutics) and historical sales decline in adult AFRISA segments despite pediatric growth.
• Clinical uncertainty exists regarding the long-term durability of efficacy for inhaled therapies and the feasibility of combining multiple oral and inhaled agents in practice.
• Regulatory hurdles remain for Mankind's inhaled Nantetinib to secure an IPF label, as the FDA typically requires dedicated efficacy trials for new indications.

Management Commentary and Tone:

• Mankind CEO Mike Castagna expressed high confidence in the pipeline, describing the company's financial and strategic position as "never looking brighter," despite the stock trading at recent lows.
• Vicor CEO Ahmed Moussa maintained a measured but optimistic tone, emphasizing the durability of their Phase 2a signal and the market need for better-tolerated therapies, while acknowledging standard caution around uncontrolled data.
• Both management teams emphasized a strategic pivot toward combination therapies and improved tolerability as the primary bar for future market success.
• Management highlighted a strategic "two CEOs, two angles" approach, with Mankind leveraging inhaled delivery expertise and Vicor focusing on unique epithelial regeneration mechanisms.

Analyst Questions and Answers:

• Question: What efficacy metric defines a "win" for Vicor's Phase 2b? Answer: Vicor targets a 65-70ml FVC difference from placebo (comparable to nardamilast), though a lower bar might be accepted given the therapy's superior tolerability profile.
• Question: Will Vicor's Phase 2b data support a filing or is Phase 3 required? Answer: Phase 3 will be required for filing; the Phase 2b is registrational quality data.
• Question: How will Mankind monetize the inhaled Nantetinib IPF opportunity? Answer: Likely requires a Phase 3 trial; Mankind hopes for a single trial to establish IPF efficacy and potentially extrapolate to PPH, though FDA conservatism on mechanism of action suggests distinct efficacy studies.
• Question: What is the sales trajectory for Fero6? Answer: In the first three weeks, 90% of new prescriptions were for the auto-injector; Q4 is projected to be a strong growth quarter.
• Question: How does Vicor address the skepticism regarding open-label Phase 2a data? Answer: The 36-week duration showed sustained improvement rather than a short-term anti-inflammatory spike, and preclinical data supports the regenerative mechanism via MMP13 upregulation.

Other Key Points:

• The discussion highlighted the "intolerability" limits of current IPF therapies (nintedanib, pirfenidone) as a key driver for new oral and inhaled agents.
• Mankind confirmed that the SC Pharma acquisition has successfully diversified revenue streams, with the Fero6 launch occurring at the end of the previous quarter.
• A "General D" (RAL DPI) program was unveiled with AI-predicted high efficacy, expected to enter human trials by year-end.
• Vicor's AT2 receptor mechanism is unique in attempting to drive fibrosis resolution rather than just slowing decline.
• The transcript concluded with a recommendation to attend a future session on AI and biotech.